GLP (Good Laboratory Practice) is a quality system for non-clinical health and environmental safety studies. It was instituted in the US after fraudulent data was submitted by toxicology labs. GLP aims to ensure studies are properly planned, monitored, and reported, and that data accurately reflects results. It promotes international acceptance of safety tests. The OECD principles provide an international standard for GLP, covering topics like facility organization, test system and item characterization, and record keeping. India has established a National GLP Compliance Monitoring Authority to oversee GLP standards.

1. WELCOME
GLP
(GOOD LABORATORY PRACTICES)

2. GOOD LABORATORY PRACTICES
1.Introduction
2.History
3.OECD principles
4.GLP at glance
5.GLP in India

3. 1.Introduction

4. 1.INTRODUCTION:
What is a good laboratory practice?

5.  Good Laboratory Practice (GLP) is a quality system
concerned with the organisational process and the
conditions under which non-clinical health and
environmental safety studies are planned, performed,
monitored, recorded, archived and reported.
Drugs-Companies
Laboratories
Government and
Company
Hazard assesment
International trade.
GLP
DATA

6. Non-clinical health and environmental safety studies
Experiments
Human beings Enviromnment
Not in a hospital

7. 2. HISTORY

8. GLP was instituted in US following cases of fraud generated by toxicology labs in data
submitted to the FDA by pharmaceutical companies. Industrial Bio Test Lab (IBT) was
the most notable case, where thousands of safety tests for chemical manufacturers
were falsely claimed to have been performed or were so poor .
1972
The word GLP- Newzealand
1976

9.  GLP was first introduced in New Zealand in 1972.
 GLP was instituted in US following cases of fraud
generated by toxicology labs in data submitted to the FDA
by pharmaceutical companies.
 Industrial Bio Test Labs (IBT) was the most notable case,
where thousands of safety tests for chemical manufacturers
were falsely claimed to have been performed or were so
poor.

10. Famous example:
In the early 70’s FDA became
aware of cases of poor laboratory
practice all over the US.
FDA decided to do an in-depth
investigation on 40 toxicology labs.
They discovered a lot fraudulent activities and a lot of poor
lab practices
Their findings were:
1. Equipment not been calibrated to standard form , therefore
giving wrong measurements.
2. Incorrect/inaccurate accounts of the actual lab study.
3. Inadequate test systems.

11.  One investigation- made headline news
 The name of the Lab was Industrial Bio Test.
Ran tests for big companies-
Procter and Gamble.
 It was discovered that mice that they had used to test
cosmetics such as lotion and deodorants had developed
cancer and died.
 Industrial Bio Test lab threw the
dead mice and covered results
deeming the products good for
human consumption.Those involved
in production,distribution and sales
for the lab eventually served jail
time.
IBT

12.  GLP was instituted in US following cases of fraud
generated by toxicology labs in data submitted to the FDA
by pharmaceutical companies. As a result of these findings,
FDA promulgated the Good Laboratory Practice (GLP)
Regulations, 21 CFR part 58, on December 22, 1978 (43
FR 59986). The regulations became effective June 1979.

13. As a international standard:
 In 1981 an organization named OECD (organization for
economic co-operation and development ) produced GLP
principles that are international standard. of the OECD
Council, data generated in the testing of chemicals in one
OECD Member Country, in accordance with OECD Test
Guidelines and the Principles of GLP are accepted in all
other OECD Member Countries.

14. INSTITUITIONS -GLP
USA FDA
INTERNATIONAL LEVEL
OECD
COUNTRY LEVEL
ORIGINATOR FOR THE GLP

15. OBJECTIVES OF GLP
 GLP makes sure that the data submitted are a true
reflection of the results that are obtained during
the study.
 GLP also makes sure that not to indulge in any
fraud activity by labs.
 Promotes international acceptance of tests.

16. 3.GOOD LABORATORY PRACTICE
PRINCIPLES

17. GOOD LABORATORY PRACTICE - PRINCIPLES
1.Test Facility Organisation and Personnel
2. Quality Assurance Programme
3. Facilities
4. Apparatus, Material, and Reagents
5. Test Systems
6. Test and Reference Items
7. Performance of the Study
8. Reporting of Study Results
9. Storage and Retention of Records and Materials

18. 1.Test Facility Organisation and Personnel
A. Test Facility Management’s Responsibilities
B. Study Director’s Responsibilities
C. Principal Investigator’s Responsibilities
D. Study Personnel’s Responsibilities

19. A.Test Facility Management’s Responsibilities.
 Responsibilities of management as defined by
these principles of good laboratory practice.
 Sufficient number of qualified personnel,
appropriate facilities, equipment, and materials are
available for the timely and proper conduct of the
Study
 Ensure the maintenance of a record of the
qualifications, training, experience.
 Job description for each professional and technical
individual.
 Documented approval of the study plan by the
Study Director.

20. B.Study Director’s Responsibilities.
 approve the study plan.
 Any amendments to the study plan by
dated Signature.
 Availability of SOPS to the personnel.
 Raw data generated are fully
documented and recorded.
 Computerised systems used in the study
have been validated.
 Sign and date the final report to indicate
acceptance of responsibility for the
validity of the data.
 Ensure that after completion (including
termination) of the study, the study
plan,the final report, raw data and
supporting material are archived.

21. C.Principal Investigator’s Responsibilities
 The Principal Investigator will ensure that the delegated
phases of the study are conducted in accordance with the
applicable Principles of Good Laboratory Practice

22. Knowledgeable
Instructions
Recording
Responsibilities
Health
precautions

23. 2.Quality Assurance Programme
1.Quality assurance personnel
2.Study plan contains the information-verification
3.conduct inspections
Study-based inspections
Facility-based inspections
Process-based inspections.
4.Records of such inspections should be retained

24. 3. Facilities
1.Test system facilities
 Sufficient number of rooms or areas assure the isolation of
test systems and the isolation of individual projects
involving substances or organisms known to be or
suspected of being biohazardous.
 There should be storage rooms or areas as needed for
supplies and equipment.
 Areas should be available for the diagnosis, treatment and
control of diseases, in order to ensure that there is no
unacceptable degree of deterioration of test systems.

25. Archive Facilities
 Archive facilities should be provided for the secure storage and
retrieval of study plans, raw data, final reports, samples of test items
and specimens.
 Archive design and archive conditions should protect contents from
untimely deterioration.
waste disposal
 Handling and disposal of wastes should be carried out in such a way
as not to jeopardise the integrity of studies. This includes provision for
appropriate collection, storage and disposal facilities, and
decontamination and transportation procedures

26. 4. Apparatus, Material, and Reagents
 Apparatus, including validated computerised systems, used for the
generation, storage and retrieval of data, and for controlling
environmental factors relevant to the study.
 Apparatus used in a study should be periodically inspected, cleaned,
maintained, and calibrated according to Standard Operating
Procedures.
 Apparatus and materials used in a study should not interfere
adversely with the test systems.
 Chemicals, reagents, and solutions should be labelled to indicate
identity (with concentration if appropriate), expiry date and specific
storage instructions. Information concerning source, preparation
date and stability should be available. The expiry date may be
extended on the basis of documented evaluation or analysis.

27. 5&6.Test Items and test systems and
characterisation

28. Drugs manufactured in the MNCs
Send to the labs for quality assurance and also testing for
the toxicity aganist to the mammals. and environment.
BioTestingLaboratory
 Test item-product going to be tested –
2.Characterization:
composition, stability, chemical nature
solubility, new formula or modified
previous product formula, identity,
potency, impurity profile,
 Test system-to which animal is going
to be administere
Results submitted to the FDA-US
Government and OECD
(International standards).
Further release into the market
and reproduction.

29. 7.Performance of the Study
1. Study Plan
2. Content of the Study Plan
3. Dates
4. Test Methods
5. Issues (where applicable)
6. Records.
7. A list of records to be retained.
8. Conduct of the Study.

30. 8.Reporting of Study Results
1. Content of the Final Report
2. Identification of the Study, the Test Item and Reference
Item
3. Information Concerning the Sponsor and the Test Facility
4. Dates
5. Statement
6. Description of Materials and Test Methods
7. Results
8. Storage

31. 9. Storage and Retention of Records and Materials
 The study plan, raw data, samples of test and reference
items, specimens and the final report of each study.
 Records of all inspections performed by the Quality
Assurance Programme, as well as master schedules.
 Records of qualifications, training, experience and job
descriptions of personnel.
 Records and reports of the maintenance and calibration of
apparatus.
 Validation documentation for computerised systems.

32. GLP AT A GLANCE

33. Product manufacturing
Testing laboratories
Non clinical and
environmental safety studies
OECD PRINCIPLES OF GLP
1.Test Facility Organisation and
Personnel
2. Quality Assurance Programme
3. Facilities
4. Apparatus, Material, and Reagents
5. Test Systems
6. Test and Reference Items
7. Performance of the Studynon
8. Reporting of Study Results
9. Storage and Retention of Records
and Materials.
INTERNATIONAL TRADE
Relesed into
the market
NON SAFETY SAFETY
Data submission to the regulated authorities - Government ,FDA

34. INDIA
GLP IN OUR COUNTRY

35.  National GLP-compliance Monitoring Authority was established by
the Department of Science & Technology
 approval of the Union Cabinet on April 24, 2002
 A provisional member of the OECD for GLP.
 India is an Observer to the OECD’s Working Group on GLP
 The Authority has trained 33 experts in the country as GLP
inspectors.

36. GLP-COMPLIANCE CERTIFICATION
The test facilities/laboratories
have to apply in the
prescribed application form
GLP-compliance Certification is
valid for a period of three years
The report, prepared by the
inspection team, is put to the
Technical Committee for
recommendation to Chairman,
National GLP- Compliance
Monitoring Authority
After the application for GLP
certification is received, a pre-inspection
of the laboratory is
carried out by the GLP
inspectors, followed by a final
inspection.

38. HEAD OF NGCMA:
Dr D R Prasada Raju
Head /Scientist G
drpraju@nic.in
National GLP Compliance Monitoring Authority
Department of Science and Technology
Technology Bhawan, New Mehrauli Road,
New Delhi-110 016 (Telefax 011-26510686)
Mrs Ekta Kapoor
Scientist D
Department of Science and Technology
Technology Bhawan, New Mehrauli Road,
New Delhi-110 016 (Phone: 011-26590242)
E-mail: -ektakapoor.glp@gmail.com

39. Our aim :
is to be get the status of full membership in the
near future so that the Indian industries do not have
to get their test facility (products) certified from
safety angle by other GLP monitoring authorities and
do not lose on the trade front.

46. Conclusion
GLP is an FDA regulation which is accepted and
approved as international standards by OECD to
avoid the fraud activities of the testing laboratories for
pesticides , pharmaceuticals , food additives , dyes, to
save the human and environmental health and also erect
good international trade and establish good relationship
among the countries .

47. Thanks a lot
PRESENTED BY
S.SRINIVAS NAIK
ID .No:13-503-010